101 related articles for article (PubMed ID: 35290538)
1. Organ-specific or personalized treatment for COVID-19: rationale, evidence, and potential candidates.
Mousavi SZ; Rahmanian M; Sami A
Funct Integr Genomics; 2022 Jun; 22(3):429-433. PubMed ID: 35290538
[TBL] [Abstract][Full Text] [Related]
2. A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection.
Mousavi SZ; Rahmanian M; Sami A
Infect Genet Evol; 2020 Dec; 86():104610. PubMed ID: 33130005
[TBL] [Abstract][Full Text] [Related]
3. Prediction of potential therapeutic drugs against SARS-CoV-2 by using Connectivity Map based on transcriptome data.
Chen WY; Fang ZX; Lv XD; Zhou QH; Yao M; Deng M
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):3122-3131. PubMed ID: 33877681
[TBL] [Abstract][Full Text] [Related]
4. Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing.
Mosharaf MP; Reza MS; Kibria MK; Ahmed FF; Kabir MH; Hasan S; Mollah MNH
Sci Rep; 2022 Mar; 12(1):4279. PubMed ID: 35277538
[TBL] [Abstract][Full Text] [Related]
5. Exploration and validation of related hub gene expression during SARS-CoV-2 infection of human bronchial organoids.
Fang KY; Cao WC; Xie TA; Lv J; Chen JX; Cao XJ; Li ZW; Deng ST; Guo XG
Hum Genomics; 2021 Mar; 15(1):18. PubMed ID: 33726831
[TBL] [Abstract][Full Text] [Related]
6. Deciphering SARS CoV-2-associated pathways from RNA sequencing data of COVID-19-infected A549 cells and potential therapeutics using in silico methods.
Natesan Pushparaj P; Damiati LA; Denetiu I; Bakhashab S; Asif M; Hussain A; Ahmed S; Hamdard MH; Rasool M
Medicine (Baltimore); 2022 Sep; 101(35):e29554. PubMed ID: 36107502
[TBL] [Abstract][Full Text] [Related]
7. Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection.
Pei R; Feng J; Zhang Y; Sun H; Li L; Yang X; He J; Xiao S; Xiong J; Lin Y; Wen K; Zhou H; Chen J; Rong Z; Chen X
Protein Cell; 2021 Sep; 12(9):717-733. PubMed ID: 33314005
[TBL] [Abstract][Full Text] [Related]
8. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.
Das AB
BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131
[TBL] [Abstract][Full Text] [Related]
9. Signaling repurposable drug combinations against COVID-19 by developing the heterogeneous deep herb-graph method.
Yang F; Zhang S; Pan W; Yao R; Zhang W; Zhang Y; Wang G; Zhang Q; Cheng Y; Dong J; Ruan C; Cui L; Wu H; Xue F
Brief Bioinform; 2022 Sep; 23(5):. PubMed ID: 35514205
[TBL] [Abstract][Full Text] [Related]
10. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.
Hasankhani A; Bahrami A; Sheybani N; Aria B; Hemati B; Fatehi F; Ghaem Maghami Farahani H; Javanmard G; Rezaee M; Kastelic JP; Barkema HW
Front Immunol; 2021; 12():789317. PubMed ID: 34975885
[TBL] [Abstract][Full Text] [Related]
11. Human pluripotent stem cell-based organoids and cell platforms for modelling SARS-CoV-2 infection and drug discovery.
Giani AM; Chen S
Stem Cell Res; 2021 May; 53():102207. PubMed ID: 33677394
[TBL] [Abstract][Full Text] [Related]
12. Identification of the Hub Genes and the Signaling Pathways in Human iPSC-Cardiomyocytes Infected by SARS-CoV-2.
Xie LM; Huang YF; Liu YL; Liang JQ; Deng W; Lin GL; Luo HM; Guo XG
Biochem Genet; 2022 Dec; 60(6):2052-2068. PubMed ID: 35235083
[TBL] [Abstract][Full Text] [Related]
13. Deciphering molecular mechanisms of SARS-CoV-2 pathogenesis and drug repurposing through GRN motifs: a comprehensive systems biology study.
Sameni M; Mirmotalebisohi SA; Dehghan Z; Abooshahab R; Khazaei-Poul Y; Mozafar M; Zali H
3 Biotech; 2023 Apr; 13(4):117. PubMed ID: 37070032
[TBL] [Abstract][Full Text] [Related]
14. An integrative bioinformatics analysis for identifying hub genes associated with infection of lung samples in patients infected with SARS-CoV-2.
Xie TA; He ZJ; Liang C; Dong HN; Zhou J; Fan SJ; Guo XG
Eur J Med Res; 2021 Dec; 26(1):146. PubMed ID: 34920753
[TBL] [Abstract][Full Text] [Related]
15. Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches.
Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ
F1000Res; 2021; 10():127. PubMed ID: 33968364
[No Abstract] [Full Text] [Related]
16. Human Induced Pluripotent Stem Cell-Derived Lung Epithelial System for SARS-CoV-2 Infection Modeling and Its Potential in Drug Repurposing.
Surendran H; Nandakumar S; Pal R
Stem Cells Dev; 2020 Nov; 29(21):1365-1369. PubMed ID: 32867617
[TBL] [Abstract][Full Text] [Related]
17. Structural Understanding of SARS-CoV-2 Drug Targets, Active Site Contour Map Analysis and COVID-19 Therapeutics.
Selvaraj C; Dinesh DC; Krafcikova P; Boura E; Aarthy M; Pravin MA; Singh SK
Curr Mol Pharmacol; 2022; 15(2):418-433. PubMed ID: 34488601
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patients.
Mahmud SMH; Al-Mustanjid M; Akter F; Rahman MS; Ahmed K; Rahman MH; Chen W; Moni MA
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33847347
[TBL] [Abstract][Full Text] [Related]
19. Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.
Ting CT; Chen BS
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409008
[TBL] [Abstract][Full Text] [Related]
20. Insights into organoid-based modeling of COVID-19 pathology.
Boroojerdi MH; Al Jabry T; Mirarefin SMJ; Albalushi H
Virol J; 2023 Feb; 20(1):37. PubMed ID: 36841795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
